145 related articles for article (PubMed ID: 28101248)
1. Expression of cancerous inhibitor of protein phosphatase 2A in human triple negative breast cancer correlates with tumor survival, invasion and autophagy.
Li S; Feng TT; Guo Y; Yu X; Huang Q; Zhang L; Tang W; Liu Y
Oncol Lett; 2016 Dec; 12(6):5370-5376. PubMed ID: 28101248
[TBL] [Abstract][Full Text] [Related]
2. Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer.
Yin J; Chen D; Luo K; Lu M; Gu Y; Zeng S; Chen X; Song Y; Zhang Z; Zheng G; He Z; Liu H
J Cancer; 2019; 10(24):5964-5974. PubMed ID: 31762806
[TBL] [Abstract][Full Text] [Related]
3. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
4. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
5. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells.
Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF
Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514
[TBL] [Abstract][Full Text] [Related]
6. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
7. Expression and biological role of CIP2A in human astrocytoma.
Yi F; Ni W; Liu W; Bai J; Li W
Mol Med Rep; 2013 May; 7(5):1376-80. PubMed ID: 23467938
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
9. CIP2A is associated with human breast cancer aggressivity.
Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
[TBL] [Abstract][Full Text] [Related]
10. Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the Discovery of drug candidates against triple negative breast cancer (TNBC).
Ibitoye O; Ibrahim MAA; Soliman MES
J Recept Signal Transduct Res; 2023 Dec; 43(6):133-143. PubMed ID: 38166612
[TBL] [Abstract][Full Text] [Related]
11. CIP2A is overexpressed in human endometrioid adenocarcinoma and regulates cell proliferation, invasion and apoptosis.
Yu N; Zhang T; Zhao D; Cao Z; Du J; Zhang Q
Pathol Res Pract; 2018 Feb; 214(2):233-239. PubMed ID: 29274810
[TBL] [Abstract][Full Text] [Related]
12. CIP2A, an oncoprotein, is associated with cell proliferation, invasion and migration in laryngeal carcinoma cells.
Chen XD; Tang SX; Zhang JH; Zhang LT; Wang YW
Oncol Rep; 2017 Aug; 38(2):1005-1012. PubMed ID: 28656258
[TBL] [Abstract][Full Text] [Related]
13. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of sCIP2A levels in breast cancer.
Xing ML; Lu YF; Wang DF; Zou XY; Zhang SX; Yun Z
Eur Rev Med Pharmacol Sci; 2016; 20(1):82-91. PubMed ID: 26813457
[TBL] [Abstract][Full Text] [Related]
16. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
17. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-218 inhibits the cell proliferation and migration in clear cell renal cell carcinoma through targeting cancerous inhibitor of protein phosphatase 2A.
Wei R; Ye X; Zhao Y; Jia N; Liu T; Lian W; Wei H; Zhang G; Song L
Oncol Lett; 2019 Mar; 17(3):3211-3218. PubMed ID: 30867751
[TBL] [Abstract][Full Text] [Related]
19. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
20. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
